EA201991641A1 - Лекарственные соединения и пищевые добавки - Google Patents

Лекарственные соединения и пищевые добавки

Info

Publication number
EA201991641A1
EA201991641A1 EA201991641A EA201991641A EA201991641A1 EA 201991641 A1 EA201991641 A1 EA 201991641A1 EA 201991641 A EA201991641 A EA 201991641A EA 201991641 A EA201991641 A EA 201991641A EA 201991641 A1 EA201991641 A1 EA 201991641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
food additives
medicinal compounds
combinations
various
carrier
Prior art date
Application number
EA201991641A
Other languages
English (en)
Russian (ru)
Inventor
Андреа Леоне-Бэй
Грегори Уэснер
Original Assignee
Ресептор Холдингз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62790943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201991641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ресептор Холдингз, Инк. filed Critical Ресептор Холдингз, Инк.
Publication of EA201991641A1 publication Critical patent/EA201991641A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201991641A 2017-01-03 2018-01-03 Лекарственные соединения и пищевые добавки EA201991641A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Publications (1)

Publication Number Publication Date
EA201991641A1 true EA201991641A1 (ru) 2020-03-10

Family

ID=62790943

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991641A EA201991641A1 (ru) 2017-01-03 2018-01-03 Лекарственные соединения и пищевые добавки

Country Status (14)

Country Link
US (2) US20190336472A1 (cg-RX-API-DMAC10.html)
EP (1) EP3565539A4 (cg-RX-API-DMAC10.html)
JP (3) JP7281815B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190103302A (cg-RX-API-DMAC10.html)
CN (1) CN110121337A (cg-RX-API-DMAC10.html)
AU (2) AU2018206564B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019013743A2 (cg-RX-API-DMAC10.html)
CA (1) CA3049226A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019001832A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019008176A2 (cg-RX-API-DMAC10.html)
EA (1) EA201991641A1 (cg-RX-API-DMAC10.html)
IL (1) IL267831A (cg-RX-API-DMAC10.html)
MX (1) MX2019007968A (cg-RX-API-DMAC10.html)
WO (1) WO2018129097A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2019144221A1 (en) * 2018-01-29 2019-08-01 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
AU2019357608A1 (en) * 2018-10-10 2021-05-27 Tilray, Inc. Methods and formulations for treating chemotherapy-induced nausea and vomiting
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
JP2023505351A (ja) 2019-12-09 2023-02-08 ニコベンチャーズ トレーディング リミテッド 口腔用組成物のための薬剤
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
ES2687098T3 (es) * 2010-11-25 2018-10-23 Aop Orphan Pharmaceuticals Ag Composiciones de disgregación rápida que comprenden nabilona y beta ciclodextrina metilada de manera aleatoria
EP2747563A4 (en) * 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CN109069475B (zh) * 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201991641A1 (ru) 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки

Also Published As

Publication number Publication date
IL267831A (en) 2019-09-26
US20230293479A1 (en) 2023-09-21
JP2020503357A (ja) 2020-01-30
US20190336472A1 (en) 2019-11-07
KR20190103302A (ko) 2019-09-04
CL2019001832A1 (es) 2020-01-31
JP7466238B2 (ja) 2024-04-12
EP3565539A4 (en) 2020-08-12
JP2023071697A (ja) 2023-05-23
AU2018206564A1 (en) 2019-08-15
AU2018206564B2 (en) 2023-12-07
BR112019013743A2 (pt) 2020-01-21
AU2024201078A1 (en) 2024-03-07
CO2019008176A2 (es) 2019-08-20
CA3049226A1 (en) 2018-07-12
JP7281815B2 (ja) 2023-05-26
CN110121337A (zh) 2019-08-13
MX2019007968A (es) 2019-12-05
WO2018129097A1 (en) 2018-07-12
JP2024075724A (ja) 2024-06-04
EP3565539A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
EA201991289A1 (ru) Быстродействующие лекарственные соединения и пищевые добавки растительного происхождения
CO2019008176A2 (es) Compuestos medicinales y suplementos nutricionales
EA202090889A1 (ru) Травяные композиции с улучшенной биодоступностью
CO2018011299A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
EA201992247A1 (ru) Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
UY37920A (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
EA201890450A1 (ru) Циклические динуклеотидные соединения в качестве агонистов sting
MX2020009390A (es) Suministro transdermico y/o dermico de agentes activos lipofilicos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX388858B (es) Reducción de la viscosidad de formulaciones farmacéuticas
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690785A1 (ru) Новая комбинированная терапия острого миелоидного лейкоза (омл)
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
ECSP21017326A (es) Composiciones alimenticias y composiciones de aditivos para piensos para especies de acuicultura
EA202091226A1 (ru) Применение лигниновой фракции в качестве ингредиента пищевой добавки для человека и животных
EA201991988A1 (ru) Композиции и способы для способствования росту волос с помощью ингибиторов mpc1
EA201791985A1 (ru) Архебактерии в составе биологически активной кормовой добавки, способы получения композиции и способы применения композиции
EA201691741A1 (ru) Фармацевтическая композиция
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA201401200A1 (ru) Новая композиция альфентанила для лечения острой боли
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye
AR106090A1 (es) Métodos y formulaciones para reducir las emisiones de bovino
RU2015110859A (ru) Композиции для пилинга, содержащие трихлоруксусную кислоту (тху) и фенол для снижения жжения, вызванного пилингом с применением тху
EA201490192A1 (ru) Добавки и композиции для животных, содержащие растворимый монензин, и способы для них